MARINOMED BIOTECH AG [CBOE] overview

EQS-News: Marinomed Biotech AG / Key word(s): Market Launch Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria 10.04.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria Carragelose eye drops for the treatment of dry eyes launched under the trade name “Coldamaris protect” in Austria Eye drops complement existing Carragelose product portfolio...

EQS-News: Marinomed Biotech AG / Key word(s): Miscellaneous Marinomed focuses on growth after successful restructuring 27.03.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed focuses on growth after successful restructuring Marinomed plans to achieve an operating profit in 2025 Budesolv: innovation for the treatment of allergic rhinitis Switzerland as a stepping stone for global expansion Korneuburg, Austria, 27. March 2025 – Marinomed...

EQS-News: Marinomed Biotech AG / Key word(s): Disposal/Strategic Company Decision Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals 28.02.2025 / 10:20 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals All requirements for closing the deal, including shareholders’ approval and ending of the...

EQS-News: Marinomed Biotech AG / Key word(s): Personnel Marinomed Biotech AG: Changes to the Management Board 31.01.2025 / 12:10 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Changes to the Management Board CFO Pascal Schmidt is resigning at the end of January 2025 Gabriele Ram, former Wienerberger AG, takes over the management of the finance department on an interim basis Restructuring proceedings successfully completed, financing of the...

EQS-News: Marinomed Biotech AG / Key word(s): Insolvency/Restructure of Company Marinomed Biotech AG: Restructuring proceedings successfully completed 20.01.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Restructuring proceedings successfully completed Restructuring proceedings formally ended by resolution of the Korneuburg regional court after meeting all necessary conditions, including unanimous approval of the restructuring...

EQS-News: Marinomed Biotech AG / Key word(s): Strategic Company Decision/AGM/EGM Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division 19.12.2024 / 12:39 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division Required majority of shareholders vote in favour of the sale of the Carragelose business unit Proceeds from the sale ensure implementation...

EQS-News: Marinomed Biotech AG / Key word(s): Restructure of Company/Insolvency Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved 17.12.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved Funds deposited for cash quota and to cover legal costs European Investment Bank (EIB) agrees to standstill...

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital Increase Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share 05-Dec-2024 / 14:34 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this...